Roche’s Gazyva shows strong phase III results for treatment of idiopathic nephrotic syndrome
Key secondary endpoints also demonstrated statistically significant and clinically meaningful benefits with Gazyva
Key secondary endpoints also demonstrated statistically significant and clinically meaningful benefits with Gazyva
The new algorithm will be introduced as part of Roche’s CKD Algorithm Panelon thenavify Algorithm Suite
The platform is being introduced to expand access to treatments for people living with chronic conditions
EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
The medicine was well tolerated, with no unexpected safety issue
Pfizer's vaccine helps protect against clinically relevant 20 serotypes responsible for a majority of invasive and non-invasive pneumococcal disease
Quest will now offer dialysis-related clinical testing services to independent dialysis clinics
Subscribe To Our Newsletter & Stay Updated